search
Back to results

Functional Neural Regeneration Collagen Scaffold Transplantation in Acute Spinal Cord Injury Patients

Primary Purpose

Acute Spinal Cord Injury

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Functional collagen scaffold
Sponsored by
Chinese Academy of Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Spinal Cord Injury

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female, 18-65 years old.
  2. Completely spinal cord injury at the cervical and thoracic level (C4-T12).
  3. Classification ASIA A, occurring within past 21 days.
  4. Patients signed informed consent.
  5. Ability and willingness to regular visit to hospital and follow up during the protocol Procedures.

Exclusion Criteria:

  1. A current diagnosis of any primary diseases affecting limb functions (e.g., trauma, infection, tumors, congenital malformations, peripheral muscular dystrophy, Huntington's disease, Parkinson's disease).
  2. Serious complications (e.g., hydronephrosis due to renal insufficiency, severe bedsores (Ⅲ° above), lower extremity venous thrombosis, severe myositis ossificans).
  3. History of life threatening allergic or immune-mediated reaction.
  4. Clinically significant abnormalities in routine laboratory examinations (hematology, electrolytes, biochemistry, liver and kidney function tests, urinanalysis).
  5. History of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders.
  6. Severe arrhythmias (e.g., ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG.
  7. Lactating and pregnant woman.
  8. Alcohol drug abuse /dependence.
  9. Participated in any other clinical trials within 3 months before the enrollment.
  10. A drug or treatment known to cause effect on the central nervous system during the past four weeks.
  11. A drug or treatment known to cause major organ system toxicity during the past four weeks.
  12. Poor compliance, difficult to complete the study.
  13. Any other conditions that might increase the risk of subjects or interfere with the clinical trial.

Sites / Locations

  • First Hospitals affiliated to the China PLA General HospitalRecruiting
  • Xinqiao Hospital of Army Medical UniversityRecruiting
  • The First Affiliated Hospital of Soochow UniversityRecruiting
  • Affiliated Hospital of Logistics Universtiy of CAPFRecruiting
  • General Hospital of Ningxia Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Functional collagen scaffold

Arm Description

Functional neural regeneration collagen scaffold transplantation.

Outcomes

Primary Outcome Measures

Safety Evaluation Number of patients with adverse events
Number of patients with adverse events is as a measure of safety and tolerability after collagen scaffold transplantation.

Secondary Outcome Measures

Improvements in ASIA Impairment Scale
American Spinal Injury Assessment Scale of A, B, C, D or E will be assessed before and after transplantation.
Improvements in Electrophysiological monitoring
Somatosensory Evoked Potentials (SSEP) monitoring will be assessed before and after transplantation.
Improvements in Electrophysiological monitoring
Motor Evoked Potentials (MEP) monitoring will be assessed before and after transplantation.

Full Information

First Posted
July 26, 2015
Last Updated
December 21, 2020
Sponsor
Chinese Academy of Sciences
Collaborators
Affiliated Hospital of Logistics University of CAPF, The First Affiliated Hospital of Soochow University, First Hospitals affiliated to the China PLA General Hospital, General Hospital of Ningxia Medical University, Xinqiao hospital of Army Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT02510365
Brief Title
Functional Neural Regeneration Collagen Scaffold Transplantation in Acute Spinal Cord Injury Patients
Official Title
Safety and Efficacy of Functional Neural Regeneration Collagen Scaffold Transplantation in Complete (AISA) Acute Spinal Cord Injury Patients
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Unknown status
Study Start Date
April 2015 (undefined)
Primary Completion Date
December 2021 (Anticipated)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese Academy of Sciences
Collaborators
Affiliated Hospital of Logistics University of CAPF, The First Affiliated Hospital of Soochow University, First Hospitals affiliated to the China PLA General Hospital, General Hospital of Ningxia Medical University, Xinqiao hospital of Army Medical University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is designed to assess the safety and efficacy of functional neural regeneration collagen scaffold transplanted into acute spinal cord injury patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Spinal Cord Injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Functional collagen scaffold
Arm Type
Experimental
Arm Description
Functional neural regeneration collagen scaffold transplantation.
Intervention Type
Biological
Intervention Name(s)
Functional collagen scaffold
Intervention Description
Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
Primary Outcome Measure Information:
Title
Safety Evaluation Number of patients with adverse events
Description
Number of patients with adverse events is as a measure of safety and tolerability after collagen scaffold transplantation.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Improvements in ASIA Impairment Scale
Description
American Spinal Injury Assessment Scale of A, B, C, D or E will be assessed before and after transplantation.
Time Frame
12 months
Title
Improvements in Electrophysiological monitoring
Description
Somatosensory Evoked Potentials (SSEP) monitoring will be assessed before and after transplantation.
Time Frame
12 months
Title
Improvements in Electrophysiological monitoring
Description
Motor Evoked Potentials (MEP) monitoring will be assessed before and after transplantation.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, 18-65 years old. Completely spinal cord injury at the cervical and thoracic level (C4-T12). Classification ASIA A, occurring within past 21 days. Patients signed informed consent. Ability and willingness to regular visit to hospital and follow up during the protocol Procedures. Exclusion Criteria: A current diagnosis of any primary diseases affecting limb functions (e.g., trauma, infection, tumors, congenital malformations, peripheral muscular dystrophy, Huntington's disease, Parkinson's disease). Serious complications (e.g., hydronephrosis due to renal insufficiency, severe bedsores (Ⅲ° above), lower extremity venous thrombosis, severe myositis ossificans). History of life threatening allergic or immune-mediated reaction. Clinically significant abnormalities in routine laboratory examinations (hematology, electrolytes, biochemistry, liver and kidney function tests, urinanalysis). History of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders. Severe arrhythmias (e.g., ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG. Lactating and pregnant woman. Alcohol drug abuse /dependence. Participated in any other clinical trials within 3 months before the enrollment. A drug or treatment known to cause effect on the central nervous system during the past four weeks. A drug or treatment known to cause major organ system toxicity during the past four weeks. Poor compliance, difficult to complete the study. Any other conditions that might increase the risk of subjects or interfere with the clinical trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhifeng Xiao, Ph.D
Phone
86-10-82614420
Email
zfxiao@genetics.ac.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Sufang Han, Ph.D
Phone
86-10-82614420
Email
sufanghan22@genetics.ac.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jianwu Dai, Ph.D
Organizational Affiliation
Chinese Academy of Sciences
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sai Zhang, M.D
Organizational Affiliation
Affiliated Hospital of Logistics Universtiy of CAPF
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Huilin Yang, Ph.D
Organizational Affiliation
The First Affiliated Hospital of Soochow University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Shuxun Hou
Organizational Affiliation
First Hospitals affiliated to the China PLA General Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Hechun Xia
Organizational Affiliation
General Hospital of Ningxia Medical University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Tongwei Chu
Organizational Affiliation
Xinqiao hospital of Army Medical University
Official's Role
Study Chair
Facility Information:
Facility Name
First Hospitals affiliated to the China PLA General Hospital
City
Beijing
ZIP/Postal Code
100037
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shuxun Hou
Phone
86-10-66867350
Email
hsxortho@hotmail.com
First Name & Middle Initial & Last Name & Degree
Jiaguang Tang, Ph.D
Phone
86-10-6684837
Email
jiaguangtang@yahoo.com.cn
Facility Name
Xinqiao Hospital of Army Medical University
City
Chongqing
ZIP/Postal Code
400037
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tongwei Chu
Email
chutw@sina.com
Facility Name
The First Affiliated Hospital of Soochow University
City
Suzhou
ZIP/Postal Code
215006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huilin Yang, Ph.D
First Name & Middle Initial & Last Name & Degree
Qin Shi, Ph.D
Phone
86-512-67781169
Email
qshisz@gmail.com
Facility Name
Affiliated Hospital of Logistics Universtiy of CAPF
City
Tianjin
ZIP/Postal Code
300162
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sai Zhang, M.D
Phone
86-22-60577101
First Name & Middle Initial & Last Name & Degree
Shixiang Cheng
Phone
86-22-60577171
Email
shixiangcheng@vip.126.com
Facility Name
General Hospital of Ningxia Medical University
City
Yinchuan
ZIP/Postal Code
750004
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hechun Xia
First Name & Middle Initial & Last Name & Degree
Xueyun Liang
Email
nxmclxy@163.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
32862715
Citation
Chen W, Zhang Y, Yang S, Sun J, Qiu H, Hu X, Niu X, Xiao Z, Zhao Y, Zhou Y, Dai J, Chu T. NeuroRegen Scaffolds Combined with Autologous Bone Marrow Mononuclear Cells for the Repair of Acute Complete Spinal Cord Injury: A 3-Year Clinical Study. Cell Transplant. 2020 Jan-Dec;29:963689720950637. doi: 10.1177/0963689720950637.
Results Reference
derived
PubMed Identifier
29871514
Citation
Xiao Z, Tang F, Zhao Y, Han G, Yin N, Li X, Chen B, Han S, Jiang X, Yun C, Zhao C, Cheng S, Zhang S, Dai J. Significant Improvement of Acute Complete Spinal Cord Injury Patients Diagnosed by a Combined Criteria Implanted with NeuroRegen Scaffolds and Mesenchymal Stem Cells. Cell Transplant. 2018 Jun;27(6):907-915. doi: 10.1177/0963689718766279. Epub 2018 Jun 5.
Results Reference
derived

Learn more about this trial

Functional Neural Regeneration Collagen Scaffold Transplantation in Acute Spinal Cord Injury Patients

We'll reach out to this number within 24 hrs